Lundbeck adds a Parkinson's flop to its list of setbacks, writing off a $1.1 billion deal on mid-stage failure

Anders Götzsche’s shot at R&D glory has ended in defeat at Lundbeck.

The Lundbeck CFO was acting chief when he struck a $1.1 billion deal to snare Prexton Therapeutics and its single asset — foliglurax — after Kåre Schultz jumped ship to run Teva. Götzsche agreed to pay €100m in cash and up to €805m in development and sales milestones to get the one-drug company.